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Summary The screening histories of all 348 women with invasive cervical cancer diagnosed in 1992 in 24 self-
selected district health authorities and health boards in England, Wales and Scotland were compared with
those of 677 age- and residency-matched controls. The controls were randomly selected from the family health
services authority (FHSA) register. Screening histories, comprising the dates and results of all smears taken
before the date of diagnosis of the patient's cancer, were determined from the FHSA computer and laboratory
records. We estimate that the number of cases of cervical cancer in participating districts in 1992 would have
been 57% (95% confidence interval 28-86%) greater if there had been no previous screening. In women under
the age of 70 it would have been approximately 75% (31 -115%) greater. Extrapolation of the results from this
pilot suggests that screening prevented between 1100 and 3900 cases of invasive cervical cancer in the UK in
1992. Women with stage lB cancer or worse were more likely to have no record of previous screening than
controls: 47% of these women under the age of 70 had been adequately screened according to current (5 yearly
screening) guidelines, compared with 75% of matched controls. Thirteen per cent of all patients under age 70
had screening histories indicative of inadequate follow-up of smears requiring colposcopy. The proportion of
microinvasive cases with screening predating diagnosis was similar to the proportion of controls. There was a
strong correlation between stage and age: 56% of cancers in women under 35 were microinvasive compared
with just 9% in women 65 years or over. The 'relative protection' following a negative smear was greatest in
the first 12 months and fell off towards the end of the fifth year. These data suggest that full adherence to
current guidelines could perhaps have prevented another 1250 cases, but additional steps would have been
required to prevent some of the 2300 remaining cases in women under the age of 70.
Keywords: audit; cervical screening; Pap smear; screening
Mortality from cervical cancer in the UK has fallen by over
30% since the introduction of screening in the 1960s.
However, much of this is because of falling rates in older
women and could be a cohort effect unrelated to screening.
The need for an effectively managed national programme was
realised by the mid-1980s (ICRF, 1984; RCOG, 1987). This
led to the introduction of a computerised call and recall
system for women aged between 20 and 64, central to the
current programme, in 1988. The invitation-based system,
together with target payments for general practitioners, has
improved coverage from between 40% and 60% in 1989 to
80% in 1992 and 83% in 1993 (Department of Health, 1994).
Considerable effort has gone into improving smear taking
and reading, and the follow-up of women with abnormal
results since 1988.
Despite the improved coverage and management, it is
necessary to examine whether screening is achieving its goal
of reducing the incidence of cervical cancer and identify areas
of current practice for improvement. In 1991 we proposed a
procedure for regular auditing of the NHS Cervical Screening
Programme using routinely collected data (LINKS, 1992).
The design was purposely kept simple and only essential data
were collected. Such an audit could also serve as the first step
of a more in-depth enquiry that may be required from time to
time. This paper reports on the pilot phase of a National Co-
ordinating Network project in which 24 districts from
England, Wales and Scotland participated and covers
cancers diagnosed in 1992. The aim of the pilot was to
study the feasibility of using a common protocol in multiple
districts to audit local programmes and to provide important
up-to-date information on the performance of the national
programme by pooling core data. The pooled data could be
used to determine the importance of coverage, screening
interval and follow-up of abnormal smears in preventing
invasive disease. Further calculations yield estimates of the
proportion of cancers that have been prevented by the
current screening programme and the potential for further
reductions associated with improvements in these aspects of
the programme. We are thus able to assess the effectiveness
of cervical screening despite the absence of randomised
controlled trials. The local data can then be used to identify
priorities for future local spending. Data presented here are
from the pilot only and the estimates obtained should be
regraded as preliminary. They indicate the sort of results that
would be available if the protocol was routinely used in all
districts. Nevertheless, we believe that the estimates presented
here are the best available for the UK screening programme.
Materials and methods
Following group discussions a protocol was adopted and
publicised through the National Co-ordinating Network for
Cervical Screening (LINKS, 1992). The 24 self-selected
districts included in the pilot come from 9 of the 14 English
regions (1992 boundaries) plus Wales and Scotland. Lists of
all cases of invasive, including microinvasive, cervical cancer
were obtained from local pathology laboratories. Local
coordinators recorded the date of diagnosis, stage and
histology together with date of birth and certain identifying
details such as name and address of each case. The
coordinators sought two age-matched controls per case
from the computerised registry held by the local family
health services authority (FHSA). This contains a list of all
people registered with a local general practitioner (GP)
together with certain information including details of
cervical smears. Since women who have had a hysterectomy
are excluded from routine cervical screening, this information
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should also be recorded on the FHSA computer. One control
was registered with the same GP as the case and the other,
though from the same district, was registered with a different
group practice. Controls with no screening history were
included. Women known to have had a hysterectomy were
excluded. The GP control was intended to give a partial
match for social class. We realised that this might lead to
overmatching since coverage is influenced by the enthusiasm
of the individual GP, not just by the socioeconomic mix of
the population. For this reason a second control from a
different group practice was used. One district only sought
GP controls, so there are not quite two controls per case
overall. Screening histories were obtained from records held
on the FHSA computer and from cytology laboratories. No
attempt was made to obtain more detailed or complete data
from GP notes. Anonymised data were sent to one of the
authors (PDS) for collation and analysis. Districts were
encouraged to obtain information on treatment where
relevant. Several found that the standard protocol revealed
aspects of their programmes that could be improved and this
was done, thus completing the audit cycle.
Microinvasive cases (FIGO stage 1A) are considered
separately from other cases in most analyses. This is because
they have excellent prognosis and may be regarded as partial
successes ofthe screening programme, in that most would not
have been diagnosed with such good prognosis in the absence
of screening.
For the purpose of this study we defined a negative smear
to be one with negative cytology (code 2) that did not
immediately follow a previous borderline or dyskaryotic
smear. (Thus the second consecutive smear with negative
cytology following a borderline or worse test will be classified
as negative). We also adopted a formal definition of
cytological results that would lead to colposcopy. The
following point system is based on current recommenda-
tions. Counting moderate or severe dyskaryosis as three
points, mild dyskaryosis as two and borderline changes as
one point, women should be referred for colposcopy when
they have accumulated at least three points from their smear
results: two consecutive negative smears wipes the slate clean.
Formal comparisons between cases and controls were
made using conditional logistic regression (Breslow and Day,
1980). Population attributable risks were calculated using the
techniques appropriate to matched case-control data (Kuritz
and Landis, 1988). The attributable risks are presented as
percentages of the actual rate of cervical cancer, rather than
of the estimate of the rate that would have existed in the
absence of screening. One analysis considers the time to the
most recent adequate cervical smear excluding (in both cases
and controls) any within 6 months of diagnosis of the case's
cancer. In this way we attempt to discover whether diagnosis
of cervical intraepithelial neoplasia (CIN) following positive
cytology helps to prevent invasive cancer. We take the
pragmatic view that where invasive cancer is diagnosed
within 6 months of a non-negative smear, that smear may
have resulted from symptoms. Inevitably, however, some will
have been asymptomatic.
Results
Of the 348 cases, 90 were known to be microinvasive (lA)
and 186 were known to be stage 1B or worse. Of the
remainder, 24 were stage 1 (not specified A or B) and 48 were
of unknown stage. At least 72% of cancers in women aged
under 50 were stage 1. There was a clear association between
stage and age. Fifty-six per cent of cases under 35 years were
definitely stage IA, compared with 14% of those aged 65 to
74 years and none ofthose aged 75 or older. We use the term
'fully invasive' to refer to those invasive cancers not known
to be microinvasive.
From Table I it can be seen that 45% of the fully invasive
cases had no smears recorded other than possibly within 6
months of diagnosis. The comparative figures are 29% for
controls (P=0.002) and 21% for microinvasive cancers. In
this respect stage 1A cases were not significantly different
from the controls (P=0.27). Coverage was strongly
dependent on age, with a steady decline in coverage with
increasing age. Cases were more likely to have no screening
history than controls in all but the oldest age group (75+).
Table II considers compliance with screening guidelines
formally introduced in 1992 (Duncan, 1992). Before this there
were no accepted national guidelines. Since the screening
programme invites women up to the age of 64, it could be
argued that women aged 65-69 in 1992 should have been
screened in the previous 5 years (i.e. between 6 months and
5.5 years before the date of diagnosis). Approximately half of
the cases under the age of 70 appear to have been adequately
screened and followed up within the previous 5 years.
However a substantial proportion arose in women who had
had a previous non-negative result which apparently was not
adequately followed up by today's standards. Whereas fewer
than 0.5% of controls had evidence of inadequate cytological
follow-up, 5% of cases had a borderline or mildly
dyskaryotic result with no cytological follow-up within the
next 6 months. In a further 8% of cases, diagnosis occurred
at least 6 months after a dyskaryotic smear warranting
colposcopy. Some of these women will have developed cancer
after unsuccessful treatment, but the routine nature of our
data was not adequate to determine how many.
The remaining analyses concentrate on women aged 64 or
less because few older women had any recorded screening.
Table I Percentage of women with no screening history up to 6
months before diagnosis
Age (years) Microinvasive Fully invasive Controls
20-34 3% (1/35) 14% (5/36) 9% (12/139)
35-49 21% (7/34) 29% (22/77) 13% (28/215)
50-64 50% (7/14) 43% (27/63) 26% (40/154)
65-74 57% (4/7) 68% (36/53) 60% (68/113)
75 + (0/0) 90% (26/29) 91% (51/56)
All ages 21% (19/90) 45% (116/258) 29% (199/677)
Table II Compliance with recommended screening in women aged under 70 years, 6 months before diagnosis
Microinvasive Fully invasive Controls
(n =89) (n =205) (n =571)
Inadequate coverage
No history 20% 36% 19%
30% 41% 24%
No test in 5 year interval 10% 6% 6%
Inadequate follow-up
Of one abnormal test 4% 5% ) 0.5%
After result requiring 17% 11% 1%
colposcopy 12% 6% ) 0.5%
Adequate screening history 53% 47% 75%Table III classifies screening histories according to a woman's
worst smear ignoring those taken within six months of
diagnosis. (A similar 6 month exclusion is applied to
controls). For the microinvasive cancers, 18% had no
previous screening history, whereas 39% had had an
abnormal or positive test. In contrast, 31% of the other
cases had no previous history and only 20% had a previous
non-negative result. Disconcertingly, 48 women (18.5% of
259 aged under 65) developed invasive cancer within 3 years
of a negative result: 19 were known to be stage lB or worse.
There was not a significant difference between the propor-
tions of cases and controls with an abnormal or positive test
followed by two consecutive negative smears (matched
Mantel -Haenszel X2i =2.9, P =0.09). Eighteen (22%) micro-
invasive cases and 15 (8.5%) fully invasive cancers were
diagnosed more than 6 months after a screening result
requiring colposcopy (by our scoring system). In half of these
women the time interval was over a year. A further 11 cases
(four microinvasive) had no smears within 12 months of a
single borderline or mildly dyskaryotic test. It is possible that
some of these women had had colposcopy without our
knowledge, but nevertheless this indicates a deficiency in the
fail-safe system.
Table IV looks at the risk of developing fully invasive
cervical cancer as a function of the number of years since a
negative smear result (IARC, 1986). Apart from excluding
microinvasive cancers, no attempt has been made to treat
screen-detected cases differently from symptomatic ones.
There is a general trend with time from last negative smear,
with a relative protection of approximtely 5.6 (= 1/0.18) in
the first year decreasing to approximately 3.1 in the fourth
year and 1.6 after between 48 and 65 months.
The percentage of women whose most recent negative test
was within a given time interval is plotted in Figure 1
separately for controls, microinvasive and other cases. The
figure shows that controls are far more likely than the cases to
have had a recent negative test. Over the 4 years before case
diagnosis, controls were screened at a steady rate of 16.5% per
year. As expected, stage 1A cases were extremely unlikely to
have had a negative resultjust before diagnosis (since most are
screen detected), but the cumulative percentage of micro-
invasive cases with a negative result becomes indistinguishable
from that of the other cases after 3 or 4 years. The figure also
shows that very few controls had their first negative smear
between 5 and 6 years before inclusion in the study, but that
this was quite common among cases. This presumably reflects
women whose cancers were diagnosed after a routine
screening test 5 years after a previous negative result.
Analyses that focus on the period of low risk following a
negative test will overestimate the reduction in risk due to
screening overall because women with abnormal or positive
smears may go on to develop cancer. To study the protection
given by participation in the screening programme, we also
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considered the time to the last adequate smear (i.e. one that
was not classified as inadequate on cytology) excluding all
those within 6 months of diagnosis. Table V shows the
estimated relative risks of developing cervical cancer more
than 6 months after any smear test. It is apparent from the
table that the risk of disease is greater in the first year
(months 7-12) than in years 2-5. This reflects those cancers
that are not diagnosed within 6 months of an initial positive
or abnormal test. Data in Tables I and V can be used to
estimate the proportion of cervical cancer that has been
prevented by screening in the five years between 1988 and
Table IV Odds ratios for cervical cancera by time elapsed since lase
negativeb smear based on all 258 fully invasive cases and their 498
matched controls
Months since last % of cases OR (95% CI)
negative smear
0-11 6 0.18 (0.09-0.35)
12-23 8 0.33 (0.18-0.61)
24-35 9 0.26 (0.14-0.47)
36-47 7 0.32 (0.17-0.56)
48-65 11 0.64 (0.36-1.14)
> 66 or no previous test 60 1.00
aExcluding those cases known to be microinvasive. bExcludes
negative tests that immediately follow a non-negative test.
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Figure 1 Distribution of the time since the most recent negative
smear test in cases and controls. Women are only included while
they are aged between 20 and 64 years.
Table IH Breakdown of screening histories of women under 65 years old up to 6 months before diagnosis
Screening history Microinvasive Fully invasive Controls
No history 15 (18%) 54 (31%) 80 (15%)
All negative
Most recent within
3 years 9 (11%) 39 (22%) 241 (48%)
4-5 years 12 (14%) 25 (14%) 118 (23%)
over 5 years 15 (18%) 22 (13%) 41 (8%)
One borderline or mild
Followed by two negatives 3 (4%) 3 (2%) 10 (2%)
Diganosis over 6 months later 7 (8%) 11 (6%) 5 (1%)
Cytoloty warrantng colposcopy
Followed by two negatives 4 (5%) 7 (4%) 11 (2%)
Diagnosis over 6 months later 18 (22%) 15 (9%) 2 (<1%)
Total 83 (100%) 176 (100%) 506 (100%)Estimating the efficacy of screening
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Table V Odds ratios for cervical cancer following any smear test (excluding all tests taken within 6 months of case
diagnosis and all cytologically inadequate smears)
Fully invasive Microinvasive
Monthsfrom (258 cases, 498 controls) (90 cases, 179 controls)
last smear test % of cases OR (95% CI) % of cases OR (95% CI)
6- 11 12 0.89 (0.50- 1.60) 17 0.88 (0.35-2.22)
12-23 10 0.53 (0.30-0.92) 18 0.46 (0.20- 1.07)
24-35 10 0.40 (0.23-0.70) 10 0.25 (0.10-0.62)
36-47 7 0.35 (0.19-0.63) 9 0.40 (0.15- 1.06)
48-65 9 0.67 (0.38- 1.19) 16 0.87 (0.34-2.25)
>66 or no previous 52 1.00 31 1.00
test
1992 in the districts participating in this audit. Combining the
results for microinvasive and fully invasive cancers we
estimate that the incidence of cervical cancer would have
been 57% greater (95% CI 28-86%) if there had been no
screening in the preceding 5.5 years. Restricting attention to
cancers in women under the age of 70 emphasises the benefits
of screening. We estimate that, in the absence of screening,
there would have been 75% (95% CI 31- 115%) more cancer
in women aged less than 70.
Discussion
Regular auditing and routine monitoring are essential so that
the policies and management of the screening programme can
be evaluated and improved in a cost-effective manner. In
addition to the usual process measures of quality control, it is
important to assess efficacy. The programme was designed to
prevent cancer, not just to reduce mortality, so audits should
look at invasive disease rather than death. Any woman
developing invasive cancer (particularly stage 2 or worse)
may be regarded as a failure of the programme and her
screening history should be evaluated as part of the audit.
This will enable one to determine which aspects of the
programme - attendance, follow-up of abnormal smears,
screening interval, smear reading, etc.- are associated with
the failures. Analysis of the screening histories of women
dying of cervical cancer requires information from the more
distant past and will not so accurately reflect the current
workings of the programme.
We have demonstrated that a simple protocol can identify
cases warranting further investigation by a local enquiry, and
that aggregation of anonymous data can provide valuable
information on the effectiveness of organised screening. A
confidential study of the slides from women with any
negative tests within 5 years of diagnosis could also
investigate the problem of false-negative smears. In our
population this would include over a third of fully invasive
cases in women under the age of 65.
Following software development by the FHS Computer
Unit, automatic control selection should be available in 1995.
This will make the protocol simpler to carry out and should
greatly increase the number of participating districts. The 24
districts in the pilot study were self-selected and thus
represent areas with enthusiastic personnel. Although they
are well distributed throughout Great Britain, they do not
include an inner city population. Within districts the
identification of invasive cancers is thought to be nearly
100%, although we have no means of verifying this in most
instances.
The registration rate of invasive cervical cancer in England
and Wales changed little between 1971 and 1989 despite a
20% fall in mortality over the same period (data from the
OPCS). This can partially be explained by cohort effects, but
since there have been no major advances in the treatment since
1971 the trends suggest that cancers are now being diagnosed
when their prognosis is better. It is unfortunate that FIGO
staging was not routinely recorded by most cancer registries,
since age-specific trends in stage at diagnosis should be used to
monitor the screening programme. We strongly support the
new requirement (effective from July 1993) that hospitals
should supply clinical stage when registering cervical cancers
and encourage clinicians to cooperate with the registries to
improve the completeness of such data.
Within all but the oldest age group the proportion of fully
invasive cases with no screening history is greater than that of
controls, but this is not true for microinvasive cancer (Table
II). This is presumably related to the fact that most
microinvasive cancers are asymptomatic. One consequence
of ignoring smears taken within 6 months of diagnosis was
that 21% of the microinvasive cancers were classified as
having no previous screening. In fact, 80% of these cases had
at least one smear in the 6 months before diagnosis.
However, inclusion of all smears taken within 6 months of
diagnosis would reclassify 18% of fully invasive cases, but
only 1.5% of the controls, as having been screened and so is
clearly not a viable option. Neither a 3 month exclusion nor
counting only those smears recorded as routine or
opportunistic would completely solve this problem. Screen-
ing programmes should aim to provide a service in which the
time from smear test through to histological diagnosis is no
more than 3 months. More reliable data on the reason for a
smear (routine screening or symptomatic) would be useful,
but may not be realistic from routinely recorded information.
The exclusion of all smears taken within 6 months of case
diagnosis in Table V could lead to biased estimates of the
effect of screening. In particular, if routine screening often
detects cancer 5-6 years after a previous negative test, then
Table V will overestimate the role of screening in reducing
cancer. Such overestimation will generally be limited to the
screen-detected microinvasive cancers, which in any case have
excellent prognosis. In Table V we use a baseline of 'over 5.5
years'. If instead we had calculated risks relative to 'over 6
years', the relative risk for screening in the sixth year would
be 2.39 (95% CI 0.8-6.9) for microinvasive and 1.1 (95% CI
0.5-2.3) for fully invasive cancers respectively. The relative
risks for the fifth year would become 0.52 and 0.39
respectively. This confirms that the bias is minimal for the
fully invasive cancers, and that many of the microinvasive
cancers were indeed screen detected.
The breakdown in Table II provides a useful picture of the
current state of the programme. It contrasts sharply with the
situation in Greater London in 1980 (Ellman and Chamber-
lain, 1984). Women who had not been screened within 5
years now account for only 41% of fully invasive cases aged
under 70. A further 11% appear to have had inadequate
follow-up after an abnormal or positive smear occurring at
least 12 months before diagnosis. It should be remembered
that the districts in this study are self-selected and the cancers
analysed are only those that have occurred despite their
screening programmes. We estimate that the incidence of
cervical cancer would have been 57% greater if there had
been no screening in the preceding 5 years. Although national
incidence data are not yet available for 1992, projection of
these rates nationally would suggest that there would have
been about 2000 additional cases of cervical cancer in 1992 if
it was not for the early diagnosis and treatment following
cervical screening. We feel confident that screening preventedEnb Uit gCaCy ofseg
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between 1100 (28% of 3930) and 3900 (86% of4535) cases of
cervical cancer in the UK in 1992. These figures are based on
95% confidence intervals for the percentage prevented and
upper and lower estimates of the number of cases of cervical
cancer in the UK in 1992. Improving coverage and follow-up
should prevent many, but by no means all, of the remaining
cancers: 47% of the fully invasive cancers (and 53% of the
microinvasive cancers) in women aged under 70 years at
diagnosis occurred despite what appeared to be adequate
screening and follow-up in the 5 years before diagnosis, that
is they arose either because of limitations of the test as
performed between 1988 and 1992 (false-negatives) or
because the recommended 5 year interval is too long.
However, even after allowing for these limitations, 23.5%
of the fully invasive cases under the age of 70 may be
attributed to no screening, 2% to a screening interval of over
5 years, 4.5% to inadequate follow-up of a single borderline
or mildly dyskaryotic smear and 6% to inadequate follow-up
of smear results that, by current guidelines, would warrant
colposcopy. The corresponding percentages for microinvasive
cases are 11%, 7%, 4.5% and 12% respectively. In all, an
additional 36% of cervical cancers (corresponding to
approximately 1250 women under the age of 70) might
have been prevented had 5 yearly screening and current
guidelines for follow-up been adhered to by all women.
Improvements in the quality of both smear taking and smear
reading since 1988 would lead one to expect that the
proportion of cancers preventable by cytological screening
may be somewhat greater. Additional steps will be required
to prevent some of the remaining cases, of which there are
some 2300 a year in women under 70 in the UK.
In both Tables IV and V the relative 'protection' between
4 and 5.5 years after a smear is considerably less than
between 3 and 4 years. This result however is quite sensitive
to the choice of intervals and is not apparent if the fifth
interval is taken to be 48-59 months. It is of great interest
and importance to determine precisely how the relative
protection decreases between 3 and 6 years after a screening
test. Although the optimal screeing interval cannot be
adequately determined by an audit of this size, a larger audit
using the same design as this pilot could be used to estimate
accurately the magnitude of the additional protection from
more frequent screening.
We are disturbed by the number ofwomen who developed
cancer despite smear results which, by current guidelines,
should have resulted in colposcopy at least 6 months before
diagnosis. Although many of these were diagnosed within a
year of the index smear, 18 cases were not.
In conclusion, we feel that the type of audit discussed here
should form an integral part of monitoring any cervical
screening programme. Ideally, future audits would incorpo-
rate slide reviews and questions regarding treatment of CIN
where appropriate. Other essential measures are the analysis
of trends in incidence and mortality and a continuation of
quality control and assurance programmes in laboratories. As
screening coverage improves the proportion of cases who
have been screened within 5 years will increase too. These
women represent those who develop cancer despite screening.
The success of the programme must, therefore, be measured
in conjunction with the changing incidence rates and stage
distribution of cervical cancer.
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